Obefazimod Shows Robust Anti-Fibrotic Effects and Rapid Relief in IBD, Setting Stage for Late-Stage Readouts
New Evidence: Obefazimod Reduces Fibrosis Markers by Up to 90% in Preclinical Models
Abivax’s presentation at the ECCO 2026 Congress caught the medical community’s attention for its robust demonstration of obefazimod's (ABX464) anti-fibrotic activity alongside its efficacy and safety in inflammatory bowel disease (IBD), especially Crohn's disease (CD) and ulcerative colitis (UC). For the first time, obefazimod showed striking reductions in key fibrotic and inflammatory pathways, with evidence spanning preclinical models and pooled clinical data.
In an in vitro human fibroblast model, obefazimod led to approximately 50% reduction in Pro-C3 (a marker of active fibrosis) and 30% reduction in aSMA (a marker of fibroblast activation), both with strong statistical significance (p<0.0001).
Animal studies reinforced these findings. Whether used early (as a preventive) or late (as treatment), obefazimod elicited marked improvements:
| Marker | Early Initiation (%) | Late Initiation (%) |
|---|---|---|
| Reduction in Collagen Deposition | 55 | 45 |
| Reduction in aSMA (activation marker) | 50 | 40 |
| Reduction in Fibrosis Score | 90 | 60 |
| Reduction in Disease Activity Index | 50 | 25 |
| Reduction in Ulceration/Inflammation | 65 | 35 |
These results signal a potentially breakthrough approach to the persistent challenge of fibrosis in IBD, a complication for which current therapies offer limited benefit.
Pooled Clinical Data Confirm Early and Durable Symptom Relief
In the Phase 3 ABTECT induction trials, symptomatic response with obefazimod (25mg or 50mg) was observed as early as the first week—the first time point measured. By week 2, nominally significant symptomatic remission was achieved (p-value <0.05), and improvements continued through week 8, including reductions in rectal bleeding and stool frequency scores compared to placebo.
Favorable Safety Profile Holds Up Across Over 1,200 Patients
The integrated safety analysis across more than 1,200 patients randomized to obefazimod (25mg, 50mg) or placebo reveals:
| Adverse Event | Obe-50mg (%) | Obe-25mg (%) | Placebo (%) |
|---|---|---|---|
| Serious TEAEs | 3.1 | 2.2 | 3.2 |
| Discontinuation due to TEAEs | 4.7 | 1.9 | 4.1 |
| Headaches (mild, median duration 2-3 days) | 0–1.1 (leading to discontinuation) | 0–1.1 (leading to discontinuation) | 0–1.1 (leading to discontinuation) |
Notably, serious adverse events and discontinuations were similar to placebo. Headaches—one of the more common issues—were typically mild and short-lived.
Mechanism of Action: Upregulation of miR-124 and Cytokine Modulation Supports Immune Balance
Biomarker analysis from two phase 3 induction trials found that obefazimod upregulated miR-124 in both blood and colon tissue (unadjusted p<0.0001 vs placebo) and reduced serum levels of inflammatory cytokines IL-17A and IL-6, with results indicating a return toward homeostatic levels. This mechanism offers a distinct advantage by partially modulating, rather than fully blocking, critical inflammatory pathways.
What’s Next: Major Readouts Planned for 2026
The Abivax management team is looking ahead to major near-term milestones: the Phase 3 maintenance trial readout in Q2 2026 and the Phase 2b ENHANCE-CD trial readout in Q4 2026. These results could cement obefazimod’s role as a potential new oral therapy for patients with IBD facing limited treatment options.
While clinical development always brings uncertainty, these results provide substantial evidence of obefazimod’s unique mechanism and clinical promise. Anyone tracking innovation in IBD may want to keep an eye on Abivax’s progress this year.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI